Predicting amyloid PET and tau PET stages with plasma biomarkers

Plasma p‐tau231, p‐tau181, PET Biomarkers, and Cognitive Change in Older Adults

(2022) Pierre‐François Meyer et al.   ANNALS OF NEUROLOGY

Blood GFAP as an emerging biomarker in brain and spinal cord disorders

(2022) Ahmed Abdelhak et al.   Nature Reviews Neurology

The accuracy and robustness of plasma biomarker models for amyloid PET positivity

(2022) Andréa L. Benedet et al.   Alzheimers Research & Therapy

Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET

(2022) Cécile Tissot et al.   EBioMedicine

Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive change

(2022) Denis S. Smirnov et al.   ACTA NEUROPATHOLOGICA

Antemortem plasma phosphorylated tau (181) predicts Alzheimer’s disease neuropathology and regional tau at autopsy

(2022) Madeline S. Morrison et al.   BRAIN

Blood Phosphorylated Tau 181 as a Biomarker for Amyloid Burden on Brain PET in Cognitively Healthy Adults

(2022) Emer R. McGrath et al.   JOURNAL OF ALZHEIMERS DISEASE

Differences Between Plasma and Cerebrospinal Fluid p-tau181 and p-tau231 in Early Alzheimer’s Disease

(2022) Andrea Pilotto et al.   JOURNAL OF ALZHEIMERS DISEASE

Performance of plasma phosphorylated tau 181 and 217 in the community

(2022) Michelle M. Mielke et al.   NATURE MEDICINE

Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients

(2022) Alexa Pichet Binette et al.   Alzheimers Research & Therapy

Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease

(2022) Christina B. Young et al.   JAMA Neurology

Multicenter 18F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer’s Disease

(2022) Michael Rullmann et al.   Biomolecules

Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivity

(2022) Stephen Zicha et al.   Alzheimers & Dementia

The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease

(2022) Oskar Hansson et al.   Alzheimers & Dementia

An accurate fully automated panel of plasma biomarkers for Alzheimer's disease

(2022) Sebastian Palmqvist et al.   Alzheimers & Dementia

The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease

(2022) Michael S. Rafii et al.   Alzheimers & Dementia

Plasma GFAP in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study

(2022) Antoinette O'Connor et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Evaluation of in vivo staging of amyloid deposition in cognitively unimpaired elderly aged 78–94

(2022) Malgorzata M. Michalowska et al.   MOLECULAR PSYCHIATRY

Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease

(2022) Shorena Janelidze et al.   BRAIN

Temporal Dynamics of Beta-amyloid Accumulation in Aging and Alzheimer’s Disease

(2021) William J Jagust et al.   NEUROLOGY

The cortical origin and initial spread of medial temporal tauopathy in Alzheimer’s disease assessed with positron emission tomography

(2021) Justin S. Sanchez et al.   Science Translational Medicine

Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease

(2021) Alexis Moscoso et al.   JAMA Neurology

Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study

(2021) Adam M. Brickman et al.   Alzheimers & Dementia

New insights into atypical Alzheimer's disease in the era of biomarkers

(2021) Jonathan Graff-Radford et al.   LANCET NEUROLOGY

Donanemab in Early Alzheimer’s Disease

(2021) Mark A. Mintun et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early stages of tau pathology and its associations with functional connectivity, atrophy and memory

(2021) David Berron et al.   BRAIN

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau

(2021) Niklas Mattsson‐Carlgren et al.   EMBO Molecular Medicine

Four distinct trajectories of tau deposition identified in Alzheimer’s disease

(2021) Jacob W. Vogel et al.   NATURE MEDICINE

Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau

(2021) Shorena Janelidze et al.   Alzheimers & Dementia

Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease

(2021) Pratishtha Chatterjee et al.   Alzheimers & Dementia

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease

(2021) Joana B Pereira et al.   BRAIN

Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures

(2021) Sebastian Palmqvist et al.   NATURE MEDICINE

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease

(2021) Shorena Janelidze et al.   JAMA Neurology

Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes

(2021) Michelle M. Mielke et al.   JAMA Neurology

Staging tau pathology with tau PET in Alzheimer’s disease: a longitudinal study

(2021) Shi-Dong Chen et al.   Translational Psychiatry

Blood-based biomarkers for Alzheimer's disease: towards clinical implementation

(2021) Charlotte E Teunissen et al.   LANCET NEUROLOGY

Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status

(2021) Xue-Ning Shen et al.   Translational Psychiatry

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

(2020) Shorena Janelidze et al.   NATURE MEDICINE

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration

(2020) Elisabeth H. Thijssen et al.   NATURE MEDICINE

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

(2020) Thomas K Karikari et al.   LANCET NEUROLOGY

An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders

(2020) Nicholas J. Ashton et al.   Nature Reviews Neurology

Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes

(2020) Adam S. Fleisher et al.   JAMA Neurology

18F-MK-6240 PET for early and late detection of neurofibrillary tangles

(2020) Tharick A Pascoal et al.   BRAIN

Multi-tracer model for staging cortical amyloid deposition using PET imaging

(2020) Lyduine E. Collij et al.   NEUROLOGY

Predicting future rates of tau accumulation on PET

(2020) Clifford R Jack et al.   BRAIN

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease

(2020) Niklas Mattsson-Carlgren et al.   BRAIN

Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative

(2020) Thomas K. Karikari et al.   MOLECULAR PSYCHIATRY

Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment

(2020) David S. Knopman et al.   JAMA Neurology

Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer’s disease

(2020) Andréa L Benedet et al.   BRAIN

Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum

(2020) Alexis Moscoso et al.   BRAIN

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease

(2020) Shorena Janelidze et al.   JAMA Neurology

Longitudinal tau accumulation and atrophy in aging and alzheimer disease

(2019) Theresa M. Harrison et al.   ANNALS OF NEUROLOGY

Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease

(2019) Rik Ossenkoppele et al.   NEUROLOGY

Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease

(2019) Andrea Vergallo et al.   Alzheimers & Dementia

Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease

(2019) Niklas Mattsson et al.   JAMA Neurology

Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease

(2019) Val J. Lowe et al.   Alzheimers & Dementia

High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis

(2019) Suzanne E. Schindler et al.   NEUROLOGY

Plasma and CSF neurofilament light

(2019) Michelle M. Mielke et al.   NEUROLOGY

Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography

(2019) Niklas Mattsson et al.   JAMA Neurology

The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes

(2019) Clifford R Jack et al.   BRAIN

Tau-positron emission tomography correlates with neuropathology findings

(2019) Val J. Lowe et al.   Alzheimers & Dementia

Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography

(2018) Michelle M. Mielke et al.   Alzheimers & Dementia

PET staging of amyloidosis using striatum

(2018) Bernard J. Hanseeuw et al.   Alzheimers & Dementia

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

Amyloid blood biomarker detects Alzheimer's disease

(2018) Andreas Nabers et al.   EMBO Molecular Medicine

High performance plasma amyloid-β biomarkers for Alzheimer’s disease

(2018) Akinori Nakamura et al.   NATURE

Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology

(2018) Renaud La Joie et al.   Alzheimers & Dementia

A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR

(2018) Christopher G. Schwarz et al.   JOURNAL OF ALZHEIMERS DISEASE

Correlation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology

(2018) Ruben Smith et al.   JAMA Neurology

Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease

(2017) Anne Maass et al.   NEUROIMAGE

In vivo staging of regional amyloid deposition

(2017) Michel J. Grothe et al.   NEUROLOGY

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease

(2017) Niklas Mattsson et al.   JAMA Neurology

Regional correlations between [ 11 C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort

(2017) Sang Won Seo et al.   NeuroImage-Clinical

THE TAU METER SCALE FOR THE GENERATION OF CONTINUOUS AND CATEGORICAL MEASURES OF TAU DEPOSITS IN THE BRAIN: RESULTS FROM 18F-AV1451 AND 18F-THK5351 TAU IMAGING STUDIES

(2016) Victor L. Villemagne et al.   Alzheimers & Dementia

In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum

(2016) Hanna Cho et al.   ANNALS OF NEUROLOGY

Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease

(2016) Rik Ossenkoppele et al.   BRAIN

PET Imaging of Tau Deposition in the Aging Human Brain

(2016) Michael Schöll et al.   NEURON

Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy

(2016) Liang Wang et al.   JAMA Neurology

The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET

(2015) William E. Klunk et al.   Alzheimers & Dementia

[ 18 F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: Specific detection of advanced phases of amyloid-β pathology

(2015) Dietmar Rudolf Thal et al.   Alzheimers & Dementia

Tau positron emission tomographic imaging in aging and early Alzheimer disease

(2015) Keith A. Johnson et al.   ANNALS OF NEUROLOGY

Clinicopathologic and11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum

(2015) Melissa E. Murray et al.   BRAIN

The A4 Study: Stopping AD Before Symptoms Begin?

(2014) R. A. Sperling et al.   Science Translational Medicine

[18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease

(2013) Chun-Fang Xia et al.   Alzheimers & Dementia

Brain  -amyloid load approaches a plateau

(2013) C. R. Jack et al.   NEUROLOGY

National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease

(2012) Bradley T. Hyman et al.   Alzheimers & Dementia

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study

(2012) Christopher M Clark et al.   LANCET NEUROLOGY

The Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and Sample Characteristics

(2008) Rosebud O. Roberts et al.   NEUROEPIDEMIOLOGY